New pre-clinical data shows potential protective effects of GFT505 in different types

[News]

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

More... (http://www.news-medical.net/news/20140130/New-pre-clinical-data-shows-potential-protective-effects-of-GFT505-in-different-types-of-cancer.aspx)